OneAscent Financial Services LLC Purchases 14,865 Shares of Johnson & Johnson (NYSE:JNJ)

OneAscent Financial Services LLC raised its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 122.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,034 shares of the company's stock after acquiring an additional 14,865 shares during the quarter. OneAscent Financial Services LLC's holdings in Johnson & Johnson were worth $4,332,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in JNJ. Brighton Jones LLC grew its position in shares of Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after buying an additional 6,332 shares during the period. Hudson Value Partners LLC grew its position in shares of Johnson & Johnson by 2.5% during the 4th quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock worth $5,648,000 after buying an additional 1,022 shares during the period. Washington Trust Bank grew its position in shares of Johnson & Johnson by 4.5% during the 4th quarter. Washington Trust Bank now owns 19,163 shares of the company's stock worth $2,771,000 after buying an additional 828 shares during the period. Millstone Evans Group LLC acquired a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $1,449,000. Finally, ZEGA Investments LLC acquired a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $945,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $163.65 on Friday. The company has a 50 day moving average of $154.29 and a 200-day moving average of $155.05. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49. The company has a market cap of $393.75 billion, a PE ratio of 17.50, a price-to-earnings-growth ratio of 2.19 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.68 by $0.09. The business had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 33.07%. The firm's revenue was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.82 EPS. As a group, equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 3.18%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's payout ratio is 55.61%.

Analyst Ratings Changes

A number of brokerages have weighed in on JNJ. UBS Group reaffirmed a "buy" rating and issued a $190.00 price target (up previously from $180.00) on shares of Johnson & Johnson in a research note on Thursday. Royal Bank Of Canada boosted their price objective on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a research report on Thursday. The Goldman Sachs Group raised shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and boosted their price objective for the stock from $157.00 to $172.00 in a research report on Wednesday, April 9th. Leerink Partners lowered shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and cut their price objective for the stock from $169.00 to $153.00 in a research report on Tuesday, May 13th. Finally, Sanford C. Bernstein reissued a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Eleven equities research analysts have rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $172.87.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.